• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
Grand Rounds

How Safe and Effective is Early Amniotomy During Labor Induction?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Amniotomy is commonly performed to accelerate the course of labor
    • Amniotomy may shorten labor and decrease risk of cesarean delivery when performed in spontaneous labor
  • The benefit of early amniotomy for women undergoing induction of labor (IOL) is unclear
  • Kim et al. (AJOG, 2019) examined the efficacy and safety of early amniotomy during IOL

METHODS:

  • Systematic review and meta-analysis
  • Data sources
    • Medline, Embase, and Web-of-Science databases (from conception to end-of-search date, Dec. 31, 2018)
  • Inclusion study criteria
    • RCTs
    • Comparing early amniotomy prior to active phase of labor to spontaneous or late amniotomy
    • Full articles in English
    • Singleton viable term fetus
    • Patients undergoing IOL for any indication
  • Study design and data analysis
    • Pooled data using the random-effects and fixed-effects models after assessing for the presence of heterogeneity
    • Risk of bias assessed
    • Subanalysis of nulliparous only was performed
  • Primary outcomes
    • Cesarean delivery
    • Time to delivery
  • Secondary outcomes
    • Intrapartum infectious morbidity | Operative delivery and indication for cesarean | Cord prolapse | Uterine hyperstimulation | Meconium-stained amniotic fluid | Neonatal outcomes, including NICU admission

RESULTS:

  • 7 studies | Total of 1,775 patients
    • Early amniotomy group: 884 patients
    • Late/spontaneous amniotomy group: 891 patients
    • There were differences in IOL indications noted between studies
  • Early amniotomy was associated with a shorter time to delivery
    • Mean difference –3.62 hours (95% CI, –6.09 to –1.16)
  • Subanalysis: In nulliparous women, early amniotomy was associated with a 5-hour shorter time to delivery
    • Mean difference –5.12 hours (95% CI, –8.47 to –1.76)
  • No differences found in
    • Rate of cesarean delivery: Relative risk (RR) 1.09 (95% CI, 0.80 to 1.49)
    • Rate of intrapartum infectious morbidity: RR 1.42 (95% CI, 0.77 to 2.61)
  • There were no differences in any of the other secondary outcomes evaluated
  • Only 2 cases of cord prolapse noted (data from 5 studies) both in the early amniotomy group

CONCLUSION:

  • Authors note these results are consistent with previous retrospective data Cochrane review regarding faster time to delivery
  • Cord prolapse incidence was no higher than that reported in the literature, but authors acknowledge this present meta-analysis was not powered for this outcome  
  • Authors acknowledge study limitations, including study heterogeneity and underpowered for some of the secondary outcomes including neonatal infection
  • The authors state that

Although our results show a shorter time to delivery with early amniotomy, there is no substitute for sound clinical judgment that incorporates the entire clinical context

Learn More – Primary Sources:

Role of early amniotomy with induced labor: a systematic review of literature and meta-analysis

Now You Can Get ObG Clinical Research Summaries Direct to Your Phone, with ObGFirst

Try it Free  »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

Does AROM Impact Preterm Inductions?
Does Elective Induction of Labor at 39 Weeks Gestation Lead to Improved Maternal and Newborn Outcomes?
Practical info on evidence based medicine for your women's healthcare practice
Labor Induction and an Unripe Cervix: Does it Result in More C-sections?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Download Your ObG App
HERE!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site